P2Y12 receptor antagonists (Galecto Biotech/Integrative Research Laboratories)

N/A

Report date: 2025/03/20 10:03:01
NME

Base Information

Drug NameP2Y12 receptor antagonists (Galecto Biotech/Integrative Research Laboratories)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsMyocardial InfarctionStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGalecto Biotech AB
China Registration ClassN/A

Develop Information

Active CompaniesGalecto Biotech ABIrlab Therapeutics AB
Inactive CompaniesN/A
Active IndicationsMyocardial InfarctionStroke
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A